Related by context. All words. (Click for frequent words.) 85 Initiates Clinical Trial 84 Completes Patient Enrollment 83 Receives Milestone Payment 82 Announce License Agreement 82 Initiates Phase II 82 Files IND 81 Initiates Enrollment 81 Submits Biologics License Application 81 Receives Orphan Drug Designation 81 Enrolls First 81 Initiates Clinical 80 Develop Novel 80 Submits IND 80 Announce Collaboration Agreement 80 Receives Approvable Letter 80 Presents Preclinical Data 80 Reports Preclinical Data 80 Sign Licensing Agreement 80 Gets FDA Clearance 80 Initiates Dosing 80 Presents Positive 80 Begins Dosing 79 Announce Licensing Agreement 79 Submits NDA 79 Announces FDA Clearance 79 Submits Response 79 Initiates Phase III 79 Receive Milestone Payment 79 Therapeutic Competitors Companies 78 Earns Milestone Payment 78 Completes Enrollment 78 Reveals Positive 78 Sign License Agreement 78 FDA Clears 78 Presents Preclinical 78 Present Preclinical Data 78 Files Shelf Registration Statement 78 Announces License Agreement 77 BioSante Pharmaceuticals Announces 77 Announces Licensing Agreement 77 Announce Merger Agreement 77 Licenses Patents 77 Drug Fails 77 Inc Therapeutic Competitors 77 Drug Candidate 77 FDA Okays 76 Drug Shows Promise 76 Identifies Potential 76 IG HCR ;) CO 76 Receives Favorable 76 Settle Patent Dispute 76 Obtains Exclusive License 76 Announces Discontinuation 76 Cites Positive 76 Successfully Completes Phase 76 Demonstrates Positive 76 Receives FDA Clearance 76 Achieves Primary Endpoint 76 Submits Application 75 Amends Agreement 75 Demonstrates Significant 75 Initiates Clinical Trials 75 Demonstrates Potential 75 Board Unanimously Rejects 75 Completes Dosing 75 Initiates Phase 2b 75 Significantly Improves 75 Shows Promise Against 75 Announces Poster Presentations 75 Q1 Loss Narrows 75 Initiate Clinical Trial 75 Settle Patent Litigation 75 Receives Patent 75 Announces Tentative Approval 75 Sinks Lower 75 Announces Initiation 75 Files Patent Application 75 Shows Promise 75 Awarded Qualifying Therapeutic 75 Presents Positive Preclinical 75 Q2 Loss Narrows 75 Expand Collaboration 75 Therapeutic Competitors companiesandmarkets.com adEgemonye 74 Jumps Higher 74 Welcomes Analyst Initiation 74 Genentech sanofi aventis 74 Signs License Agreement 74 Phase 2a Trial 74 Achieves Milestone 74 Receives Tentative Approval 74 Receives Orphan Drug 74 Collaborators Present 74 Arthritis Drug 74 Introduces Novel 74 Terminate Merger Agreement 74 Acquires Exclusive 74 Receives Complete Response 74 Novel Oral 74 Extends Collaboration 74 Q3 Loss Narrows 74 Inc. www.micromet inc.com 74 Provides Update Regarding 74 Announces Favorable 74 Milestone Payment 74 Voluntarily Withdraw 74 Biomarker Study 74 FDA Approves Generic 74 Collaborators Publish 74 Phase 2b Clinical Trial 74 Inc. Nasdaq OXGN 74 Completes Tender Offer 74 Launches Generic Version 74 Lung Cancer Drug 74 Anti Tumor 74 Board Authorizes 74 JAK2 Inhibitor 74 SIX RO ROG 74 Vaccine Adjuvant 74 Announce Collaboration 74 Signs Licensing Agreement 74 Regains NASDAQ 74 Receives Fast Track 74 Q4 Loss Narrows 74 Submits Supplemental 74 platform HDL Mimetic 73 Completes Merger With 73 Commercialize Novel 73 R MSCRAMM 73 Meets Primary Endpoint 73 Begins Shipment 73 Restructures Operations 73 Extend Collaboration 73 Successfully Completes Tender Offer 73 Merck OSI Pharmaceuticals 73 Antibody Drug Conjugate 73 Announces Presentation 73 FDA Accepts 73 Reports Positive 73 Q2 Adj 73 Discontinues 73 Earnings Postmortem 73 Q4 Loss Widens 73 Improves Survival 73 TM Aganocide 73 Study Demonstrates 73 Voluntarily Withdraws 73 FDA Approvals 73 Commences Phase 73 Preclinical Data 73 Awarded Patents 73 Immunotherapeutic 73 Settles Patent Dispute 73 Files Patent 73 pralatrexate injection folate analogue 73 Rheumatoid Arthritis Drug 73 Epilepsy Drug 73 candidates Azedra TM 73 Webcast Presentations 73 Lupus Drug 73 Psoriasis Drug 73 Q3 Loss Widens 73 Investigational Treatment 73 Guides Inline 72 Taglich Brothers Initiates Coverage 72 Patient Enrollment 72 Systemic Delivery 72 Shows Promising 72 Granted Orphan Drug 72 Obtains License 72 Pharma Merck Serono 72 AUDIO PROVIDED BY 72 Exercises Option 72 Novel Therapeutic 72 Initiates Phase 72 Phase 2b Trial 72 PRN FDA Approves 72 estrogen receptor beta agonist 72 Boehringer Ingelheim MedImmune 72 Files Investigational 72 Novartis Novo Nordisk 72 IND Application 72 Shows Efficacy 72 Vitrasert R 72 Announce Initiation 72 Regains Full 72 Q1 Adj 72 Receives Unsolicited 72 Q2 Loss Widens 72 Receives SFDA Approval 72 Settles Litigation 72 Announces Dosing 72 Q1 Loss Widens 72 Milestone Payments 72 Gout Drug 72 Flamel Technologies Announces 72 Reacquires 72 Completes Previously Announced 72 Metabolic Disease 72 Receives NASDAQ 72 Nasdaq PGNX 72 Announces Dismissal 72 Receives Favorable Ruling 72 Nasdaq ZGEN 72 Improves Outcomes 72 Rated Speculative Buy 71 Generic Versions 71 Kinase Inhibitor 71 Teva Provides Update 71 Unsolicited Proposal From 71 Awarded Patent 71 Xcytrin R 71 Successfully Completes Acquisition 71 Broadens Its 71 INDICATED LOWER 71 Transdermal Patch 71 Receives Positive 71 Explore Strategic Alternatives 71 lead molecular radiotherapeutic 71 Receives Commitment 71 Significantly Increases 71 Posts Wider 71 Initiates Voluntary Recall 71 Terminates Agreement 71 Obtains Exclusive Rights 71 Clinical Trial Results 71 TRACON Pharmaceuticals 71 Files Shelf Registration 71 Therapeutic Competitors Report 71 Strengthens Balance Sheet 71 Finalizes Purchase 71 Announce Definitive Agreement 71 Posts Wider Loss 71 Small Molecule 71 Finalizes Acquisition 71 developing ACAPODENE 71 Genotyping Test 71 Medisorb ® 71 Stockholders Approve Merger 71 Treatment Reduces 71 Combination REOLYSIN R 71 Provides Guidance 71 Oral Calcitonin 71 please visit http:/www.vandapharma.com 71 Initiate Phase III 71 Regains Compliance With 71 Movers Roundup 71 Announce Settlement 71 Appoints Seasoned 71 Aradigm Logo 71 Secures Financing 71 Announces Successful Completion 71 Announces Positive 71 Novartis Organon 71 Milestone Payment From 71 Taro Receives 71 4Q Loss Widens 71 Announces Definitive Agreement 71 Introduces Breakthrough 71 Successfully Concludes 71 Bearish Speculation 71 Issued Patent 71 CybeRelease Decliners 71 Merck Serono Nycomed 71 Test Detects 71 NewsBite Downgrade Puts Pressure 71 Patients Treated With 71 Anti Angiogenesis 71 Bearish MACD 71 BIOTECHNOLOGY SOURCE 71 Begins Clinical Trial 71 Assets Acquirer Company 71 Obtains Approval 71 Preclinical Study 71 Collaborates With 71 Inc. Nasdaq IMGN 71 Therapeutic Antibody 71 Stockholders Approve Acquisition 71 Receives Clearance 71 CoTherix logo 71 Announce Licensing 70 Effectively Treats 70 Announces Publication 70 Mylan Receives Approval 70 Receives Notification 70 Reports Receipt 70 Patent Issued 70 Cholesterol Lowering Drug 70 Successfully Treats 70 FDA Warns 70 Phase IIb Trial 70 Phase IIa Clinical Trial 70 Lowers Guidance 70 Announces Stockholder Approval 70 Q4 Profit Surges 70 Receives CE Marking 70 Shareholders Approve Merger Agreement 70 Obtains FDA 70 Exploit collaboration 70 NDA Submission 70 Investigational Oral 70 Announces Issuance 70 visit http:/www.mannkindcorp.com 70 Bullish Average Crossover 70 visit http:/www.PAREXEL.com 70 Namenda Memantine HCl 70 Restructures Debt 70 Finalizes Sale 70 proprietary radiolabeled monoclonal 70 Nasdaq ANPI 70 Provides Updated 70 MBRX 70 Terminates Merger Agreement 70 Summarizes 70 Reduces Risk 70 Entry Inhibitor 70 Receives Conditional 70 Prolongs Survival 70 Nasdaq XTLB 70 Shareholders Approve Acquisition 70 Exploring Strategic Alternatives 70 Settles Patent Litigation 70 Investigational Compound 70 Amend Merger Agreement 70 Completes Acquisitions 70 Develops Innovative 70 programs visit http:/www.bionovo.com 70 Unveils Innovative 70 Introduces Enhanced 70 Researchers Identify 70 Develop Next Generation 70 Corp. NASDAQ CYTR 70 Introduces Next Generation 70 Idenix Novartis 70 Files Provisional 70 Syneron logo 70 Updates Guidance 70 Telik logo TELINTRA 70 DRRX 70 Hematology Molecular Pathology 70 Vaccine Protects Against 70 Director Exercises Options 70 Osteoporosis Drug 70 Nasdaq IDIX 70 CysDisplay R 70 Disease Modifying 70 Q1 Profit Surges 70 Spins Out 70 AVI BioPharma Announces 70 Nicotine Vaccine 70 Enters Oversold Territory 70 Demonstrates Sustained 70 please visit http:/www.atherogenics.com 70 Orally Active 70 Therapeutic Competitors 70 Hsp# Inhibitor 70 novel emulsion formulation 70 Wins Patent Infringement 70 Inc. Nasdaq MITI 70 First Patient Enrolled 70 Commercializes 70 Genentech GlaxoSmithKline 70 Immunomedics Announces 70 Receives Subpoena 70 developing Zerenex ferric 70 Proves Effective 70 Announce Commencement 70 Millenium Pharmaceuticals 70 Q2 Profit Surges 70 Inflammatory Disease 70 Extends Tender Offer 70 Phase IIb Clinical Trial 70 Study Validates 70 Aeolus Pharmaceuticals Announces 70 Advanced Melanoma 70 NASDAQ ENMD 70 R lenalidomide 70 FDA APPROVES 70 VP Exercises Options 70 markets HP Acthar 70 Issues Guidance 70 Calls Purchased 70 PHRM 70 researches develops licenses 70 Post Earnings Checkup 70 Commence Phase 70 Shows Statistically Significant 70 Demonstrates Ability 70 WeissComm Partners +#-#-#-# 70 Cephalon GlaxoSmithKline 70 Announces Postponement 70 Launches Unique 70 Commercialize 69 Unveils Expanded 69 Blood Pressure Drug 69 Seeks Approval 69 Vaccine Shows Promise 69 Announces Immediate Availability 69 Crofelemer budesonide foam 69 Prostate Cancer Vaccine 69 Biotherapeutic 69 Posts Wider 4Q Loss 69 Novel Compounds 69 Regains Compliance 69 visit www.genenews.com 69 Mutually Agree 69 Consummates 69 molecular imaging radiopharmaceutical 69 Q3 Adj 69 Ups Guidance 69 Patent Covering 69 visit http:/www.neogenomics.org 69 Announce Early Termination 69 Cholesterol Drug 69 Tumor Targeting 69 Demonstrates Statistically Significant 69 Enters Into Licensing Agreement 69 Confirms Receipt 69 Reduces Workforce 69 Appoints Experienced 69 Expands Scientific Advisory 69 Q1 Profit Decreases 69 visit www.sciclone.com 69 Non Invasive Treatment 69 Files Patents 69 Commences Phase III 69 Momenta Pharmaceuticals MNTA 69 Announces Organizational Changes 69 www.palatin.com 69 Tyrosine Kinase Inhibitor 69 proprietary intranasal insulin 69 Successfully Treated 69 AMEX KAL 69 Myriad logo BRACAnalysis 69 proprietary intravenous formulation 69 Visit www.BASInc.com 69 Reduces Mortality 69 Agonist MABA program 69 Inc. Nasdaq TRMS 69 Nasdaq CTIC 69 2Q Loss Widens 69 Closes Previously Announced 69 Schizophrenia Drug 69 Dyax logo 69 Significantly Reduces 69 developing adecatumumab 69 PROFILE CO 69 Submits Investigational 69 Mouse Models 69 Updates Status 69 Attracting Bullish Investors 69 Signs Option Agreement 69 Fungal Infections 69 Protein Biomarker 69 Extend Partnership 69 RNAi Therapeutics 69 www.micromet inc.com 69 Nasdaq VNDA 69 Narrows Guidance 69 Inks Licensing Deal 69 Strengthens Position 69 Launches Next Generation 69 Announces Adjournment 69 Colaris Colaris AP 69 Unveils Revolutionary 69 Anti Inflammatory 69 Deliver Presentation 69 Net Loss Narrows 69 Exclusive License 69 Genentech Wyeth Pharmaceuticals 69 Introduces Revolutionary 69 * vwd PRN 69 Completes Recapitalization 69 Urine Test 69 Syndax Pharmaceuticals Inc. 69 Reaffirms Outlook 69 Abstract Accepted 69 Patent Lawsuit 69 targeted anticancer biopharmaceuticals 69 ALTROPANE R 69 Paris IPN Euronext 69 Reconfirms 69 Confirms Commitment 69 Naglazyme R 69 CEO Exercises Options 69 MSCRAMM ® 69 pharmacogenomic translational research 69 Treatment Shows Promise 69 Announces Divestiture 69 NASDAQ RNAI 69 Corp. AMEX CVM 69 Novel Treatments 69 developing ostarine selective 69 Posts Narrower Loss 69 technology visit http:/www.genmab.com 69 Molecular Diagnostic Test 69 Phase III Clinical Trial 69 Demonstrates Efficacy 69 Achieves Positive 69 Invites Investors 69 NeutroPhase TM 69 Webcast Annual Meeting 69 Buy Privately Held 69 Secures Additional 69 RapidMist 69 Protects Against 69 Alvine Pharmaceuticals 69 please visit http:/www.supergen.com 69 Revises Guidance 69 FDA Approves 69 Antitumor Activity 69 Newly Identified 69 Q4 Profit Soars 69 Potelligent Technology 69 Hires Lobbyist 69 Gene Linked 69 includes Dideco CarboMedics 69 Provides Updates 69 STERIS Corporation Announces 69 Hold Fourth Quarter 69 Migraine Drug 69 Expands Portfolio 69 Adipose Derived Stem Cells 69 NASDAQ MNKD focuses 69 Inc. ProMetic www.prometic.com 69 please visit www.middlebrookpharma.com 69 Develops Novel 69 please visit www.medicinova.com 69 IND Filing 68 molecular therapeutics immunotherapies 68 Acquire Assets 68 Signs Merger Agreement 68 Inc. NASDAQ ELGX 68 website www.celsion.com 68 Generic Version 68 Executes Agreement 68 Xoma Ltd 68 Explores Strategic Alternatives 68 OTCBB IGXT 68 Slow Progression 68 Receives Positive Opinion 68 Clinical Trial Evaluating 68 Thewallstreetleader.com Profiles 68 Sets Record Date 68 Transdermal Delivery 68 Endures Analyst Downgrade 68 Identifies Key 68 Jointly Announce 68 Holds Promise 68 Delivers Next Generation 68 Earnings Scorecard 68 Develops Breakthrough 68 Announce Exclusive 68 Withdraws Application 68 Announces Additions 68 Announce Launch 68 Unveils Latest 68 Catalyst Biosciences 68 Announce Availability 68 siRNA Delivery 68 manufactures minimally invasive 68 please visit www.dyax.com 68 MEK Inhibitor 68 Novel Vaccine 68 Closes Second Tranche 68 Aethlon Medical Releases 68 Moving Average Crossover Alert 68 Provides Shareholder 68 Sanofi Aventis Schering Plough 68 Receives Stockholder Approval 68 Skymark Research Initiates Independent 68 Mouse Model 68 FOLOTYN ® 68 Sirna Therapeutics StrataCom 68 markets COLAZAL 68 Q4 Profit Plunges 68 HuCAL GOLD R 68 Develop Innovative 68 Guides Below 68 Posts 2Q 68 Shown Effective 68 Begins Tender Offer 68 Proves Successful 68 Genes Involved 68 Puts Purchased 68 Files Definitive Proxy 68 Successfully Closes 68 Net Loss Widens 68 Metabolic Disorder 68 Nasdaq MNKD focused 68 novel proprietary KL4 68 Nasdaq MNKD focuses 68 Introduces Innovative 68 Completes Buyout 68 Pruvel TM 68 Dealmaking Profile 68 Inc GPRO 68 Nasdaq CYTX 68 Multiple Sclerosis Rheumatoid Arthritis 68 Announces Termination 68 Enters Into Collaboration 68 non nucleoside inhibitor 68 Lowers Risk 68 Could Revolutionize 68 FY# Loss Widens 68 Upside Looming 68 Humanized Anti 68 Therapeutic Vaccine 68 Extends Expiration Date 68 RNAi Therapeutic 68 Regains Nasdaq 68 SPL# Gel vaginal microbicide 68 Phase 1b Clinical Trial 68 Amex PTN 68 Forges Partnership 68 Daytradersdigest.com 68 Secures Funding 68 Expanded Indication 68 Announces Commencement 68 Single Dose 68 VIVUS Announces 68 Inc. Nasdaq ZGEN 68 Patent Lawsuit Against 68 Nasdaq SGEN 68 Blood Thinner 68 website http:/www.celsion.com 68 Viagra Soft Cialis Soft 68 Reschedules Fourth Quarter 68 Drug Combo 68 Biogen Genentech 68 Guides FY# Quick Facts 68 PWRM.OB 68 Completes Purchase Of 68 COO Exercises Options 68 Patent Infringement Lawsuit Against 68 Isis Pharma 68 Protein Linked 68 Shareholders Approve Merger 68 VentiRx Pharmaceuticals 68 Inc SPPI 68 Sign Definitive Agreement 68 Bearish Pressure Building 68 CNS Disorders 68 Announce Expiration 68 http:/www.pharmacopeia.com 68 Canaccord Genuity Maintains Hold 68 Files Annual Report 68 Remains Neutral 68 Nasdaq AVNC 68 Helps Detect 68 Q4 Adj 68 Stays Neutral 68 Refractory Hodgkin Lymphoma 68 Announces Cancellation 68 FDA Approves Drug 68 Nasdaq HALO 68 www.combinatorx.com 68 Aztreonam Lysine 68 DARA logo 68 Report companiesandmarkets.com adds 68 Initiate Phase 68 Diabetic Foot Ulcer 68 Completes Financing 68 Atypical Antipsychotic 68 Expands Relationship With 68 Bearish Average Crossover 68 Retains CCG Investor Relations 68 NASDAQ CRTX 68 THERAPEUTICS 68 ATRA IV 68 R Saizen R 68 oncolytic virus therapies 68 Given Outperform Rating 68 Phase 2a Clinical Trial 68 Seeks Injunction Against 68 subsidiaries visit http:/www.apricusbio.com 68 Reaffirms FY# Outlook 68 humanized therapeutic 68 Posts 4Q 68 NASH Huntington 68 Cell Transplants 68 Reports Inducement Grants 68 Completes Divestiture 68 Tibotec BVBA 68 Settle Litigation 68 pipeline ImmunoGen collaborators 68 Oral Suspension USP 68 Gets Bearish Confirmation 68 Drug Prevents 68 Receives Funding 68 visit www.targanta.com 68 Winning Streak Continues 68 Patient Treated 68 Canaccord Genuity Reiterates Buy 68 Achieves Significant 68 Slows Progression 68 CEFF financings subject 68 KAI Pharmaceuticals 68 Vascular Disrupting Agent 68 Syntonix Pharmaceuticals 68 SVP Exercises Options 68 FY# Loss Narrows 68 Shareholders Approve Sale 67 Phase III Trial 67 Genes Linked 67 Terminates Contract 67 Patent Infringement Lawsuit 67 Posts Wider 2Q 67 sanofi aventis Bayer Schering 67 CFO Resigns 67 Beats Raises Guidance 67 3Q Loss Widens 67 using VIAdel TM 67 Expand Relationship 67 Inc AMGN AMGN 67 Veronate R 67 Outlines Strategy 67 Inc FRX 67 www.qiagen.com 67 Bristol Myers Squibb Celgene 67 Begins Shipping 67 CRWEWallstreet.com Stock Report 67 treat hyperproliferative disorders 67 Bullish Technical Alert 67 TRANSDUR ™ 67 Guidelines Issued 67 Web Site http:/www.cryolife.com 67 Company website www.anormed.com 67 Kosan dependence 67 Mg Usa 67 Enzon Pharmaceuticals Inc 67 Announces Effective Date 67 FDA Panel Recommends 67 Consulting Fees Honoraria 67 please visit http:/www.sunesis.com 67 Treating Chronic 67 Q3 Profit Soars 67 Confirms Efficacy 67 Showcases Innovative 67 Tezampanel 67 Completes Initial 67 Boosts Buyback 67 Recombinant Human 67 Completes Merger 67 Unveils Groundbreaking 67 OTCQB CTIX 67 Acquire Privately Held 67 Subsidiary Enters 67 Asthma COPD 67 corticotropin injection 67 Monoclonal Antibody 67 Strengthens Its 67 Wins Summary Judgment 67 Receives Certification 67 Begin Clinical Trials 67 Bullish Engulfing Pattern 67 Bullish Speculation 67 Osteoporosis Treatment 67 Bone Metastases 67 www.pharsight.com 67 CRWESelect CRWESelect.com Highlights 67 Enters Definitive Agreement 67 Guides Above 67 FDA Approves Expanded 67 Heart Transplant Recipients 67 Beats Estimates Analyst Blog 67 Pivotal Study 67 TNF Blockers 67 Study Evaluating 67 http:/www.appliedbiosystems.com/ 67 Daiichi Sankyo Eli Lilly 67 Benzinga Volume Movers 67 candidate deforolimus 67 Patients Suffering 67 Anti Tumor Activity 67 Receives Regulatory 67 Cancer Cells 67 Personalized Immunotherapy 67 Posts Wider Than Expected 67 http:/www.unigene.com 67 narrows Quick Facts 67 Introduce Next Generation 67 Schizophrenia Treatment 67 MONSTERSTOX.COM Monsterstox.com 67 HER2 Positive 67 HuCAL PLATINUM R 67 Nasdaq ENMD 67 Insights Into 67 Plans Job Cuts 67 Backs FY# Outlook 67 Lowers Price 67 Enters Into Exclusive 67 markets Testim ® 67 Equipment Deals 67 Proven Effective 67 Unveils Breakthrough 67 Initiates Voluntary 67 Stockholders Approve Merger Agreement 67 FDA Approves Novel 67 Fast Track Status 67 Inhibits 67 Q1 Profit Declines 67 Inc. OTCBB ECTE 67 OTCBB FCSC 67 Being Studied 67 Drug Resistant 67 CFO Exercises Options 67 Previously Treated 67 Slashes Guidance 67 Adjuvant Treatment 67 OTC BB PVCT 67 Regenerative Cells 67 Horizant ™ 67 Cypress Bioscience Inc 67 Recombinant Protein 67 www.facetbiotech.com 67 Announces Enhancements 67 Miraculins Announces 67 pentadentate logo R 67 Q4 Profit Decreases 67 Closes Acquisition Of 67 Inc. NASDAQ MEDX 67 Study Indicates 67 TRANSDUR ® 67 Completes Expansion 67 INSPIRE Trial Phase III 67 Protein Synthesis 67 Less Invasive 67 Settle Patent 67 Q3 Profit Decreases 67 COMUNICADO DE 67 GVAX ® 67 Prove Effective 67 SABER ™ 67 Dramatically Increases 67 Transcept Pharmaceuticals 67 Helps Prevent 67 First Patient Treated 67 Staphylococcus aureus Immune Globulin 67 Q3 Profit Surges 67 Topical Treatment 67 Acquires Controlling Interest 67 Announces Underwriters Exercise 67 Evaluate Strategic Alternatives 67 Receives Shareholder Approval 67 Coverage Initiated 67 Restate Financials 67 Options Trader Alert 67 Patents Covering 67 Potentially Fatal 67 OTCBB ILNS 67 Scientists Identify 67 Generic Version Of 67 Sign Definitive Merger 67 Acquirer Company 67 Revises FY# Outlook 67 visit www.novabaypharma.com 67 Oral Mucositis 67 Inc CLDA 67 Frankfurt XMP 67 Inc. OTCBB CAXG 67 Puts Sold 67 Second Quarter Earnings Preview 67 Device Maker 67 Reduces Debt 67 MEMY 67 Adopts Stockholder Rights 67 Therapeutic Efficacy 67 SWOT Analysis Aarkstore Enterprise 67 Finalizes Agreement 67 EVP Exercises Options 67 Hold Third Quarter 67 Completes Asset 67 Pegloticase 67 please visit www.eisai.com 67 Inc. NASDAQ QLTI 67 Postdoctoral Position 67 Clinical Trial Enrollment 67 Releases Next Generation 67 Resumes Coverage 67 Expands Capabilities 67 Pharmacueticals 67 Host Fourth Quarter 67 NASDAQ DIGE 67 candidates Azedra 67 palonosetron hydrochloride Injection Dacogen 67 Makes Bearish 67 3Q Profit Plunges 67 Hematological Malignancies 67 Completes Transaction 67 Announces Voluntary Recall 67 HDAC Inhibitor 67 Receives Approvals 67 visit www.genmab.com 67 Signs Agreements 67 4Q Profit Doubles 67 Approve Merger 67 www.immunogen.com 67 Patients Receiving 67 Nasdaq IMGN 67 Files Patent Infringement 67 Reduces Pain 67 developing Surfactant Replacement 67 Launches Expanded 67 pharma.com 67 Valortim TM 67 Maven Semantic 67 Completes Redemption 67 Chemotherapeutic 67 Q1 Profit Soars 67 Q2 Profit Plunges 67 Broadens Scope 67 include ClindaReach TM 67 Schedules 3Q 67 Put Volume Surges 67 IMRX 67 Clinical Trial Data 67 Increases Ownership 67 Wins Approval 67 1Q Profit Triples 67 DP VPA 67 Announce Completion 67 4Q Profit Jumps 67 Announces Revised 67 Holds Annual Meeting 67 Trims Loss 67 AllPennyStocks.com Spotlights 67 Receives Accreditation 67 MOVIPREP R 67 Enters Into License Agreement 67 Aloxi ® 67 Boosts Estimates 67 Exec Exercises Options 67 Introduces Powerful 67 Launches Enhanced 67 Provides Comprehensive 67 Fentanyl Patch 67 Nasdaq TARG 67 Helps Reduce 67 Receives Approval From 67 Inc. OTCBB SPRX 67 Reach Settlement Agreement 67 visit www.noven.com 67 Narrows 4Q Loss 67 Study Identifies 67 Cholesterol Drugs 67 Receives Notice Related 67 Exherin 67 Study Sheds Light 67 Technicals Showing Bearish 67 gets USFDA nod 67 Loss Shrinks 67 Celebrates Decade 67 Adjunctive Therapy 67 Amends Terms 67 Alnylam Nasdaq ALNY 67 www.ucb.com 67 Host Webcast 67 Q2 Profit Soars 67 Q4 Profit Climbs 67 Nasdaq DVAX 67 Nasdaq ACAD 67 Announces Stock Buyback 67 Helps Predict 67 Shares Plunged What 67 Gets Clearance 67 Anti Nausea 67 Host Third Quarter 67 Receives Notice 67 COLAZAL R 67 Accelerate Commercialization 67 Bayhill Therapeutics 67 Host Teleconference 67 Completes Conversion 67 Announces Ticker Symbol 67 Narrows 1Q 67 Mg Uk 66 NicVAX TM 66 LymphoStat B TM 66 www.biosite.com 66 Small Molecule Drug 66 Posts Smaller 66 Launches Groundbreaking 66 Releases Third Quarter 66 Inhaled Insulin 66 Successfully Completed 66 Inc. Attracting Bullish 66 S. Arzerra 66 ELADUR TM 66 Delivers Solid 66 ExxonMobil Fluor 66 Receives Clearance From 66 Sangamo BioSciences Announces 66 Commences Cash 66 Roche OTC RHHBY 66 Helps Identify 66 Unveils Next Generation 66 Million Milestone Payment 66 Announce Breakthrough 66 M.D. Joins